Patients with higher expression of VPS53, FAM57A, and GEMIN4 exhibited worse disease-specific survival probability, as demonstrated in the Kaplan–Meier survival analysis on the TCGA prostate cancer cohort. This evidence concerns the gene GEMIN4 and prostate carcinoma.